Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is expressed in multiple
tissues, including the small intestine. The effect of PCSK9 inhibition on cholesterol …

The effects of cholesterol-lowering drugs, including those that reduce cholesterol synthesis
(statins) and those that reduce cholesterol absorption (ezetimibe), on cholesterol absorption …

Very few studies have investigated the interrelations between proprotein convertase
subtilisin/kexin type 9 (PCSK9) metabolism, cholesterol synthesis, and cholesterol …

Background Alirocumab undergoes target‐mediated clearance via binding of proprotein
convertase subtilisin/kexin type 9 (PCSK 9). Statins increase PCSK 9 levels; the effects of …

Background Proprotein convertase subtilisin/kexin type-9 inhibitors (PCSK9i) effectively
reduce low-density lipoprotein cholesterol (LDL-C), improving cardiovascular outcomes in …

Background: Alirocumab is a monoclonal antibody that inhibits binding of PCSK9 to LDL
receptors, decreasing their lysosomal degradation and increasing their numbers on cell …

Statin intolerance is a common problem most clinicians encounter when treating patients
taking these drugs. Balancing the symptoms of muscle aches in a patient in need of …

Aim Dyslipidemia is recognized as one of the major risk factors for cardiovascular diseases.
This retrospective observational study was aimed to assess the effect of proprotein …

Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been
shown to lower atherogenic lipid markers in patients with statin intolerance; however …

Abstract In 2015, 2 proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors,
alirocumab and evolocumab, were approved by Food and Drug Administration (FDA). Both …